Skip to main content
H.R. 2069 116th Congress House

SPIKE Act

Official title: To amend title XI of the Social Security Act to provide for drug manufacturer price transparency.

Introduced: April 30, 2019 Introduced by: Steven Horsford Democratic · Nevada See on congress.gov
Health Business recordsCivil actions and liabilityCorporate finance and managementGovernment information and archives
More subjectsShow fewer subjects
Health care costs and insuranceInflation and pricesManufacturingPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 21, 2019
Subcommittee Hearings Held.
Apr 4, 2019
Referred to the Subcommittee on Health.
Apr 3, 2019
Referred to the Subcommittee on Health.
Apr 3, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 3, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action May 21, 2019

Subcommittee Hearings Held.

 Plain-English summary Congressional Research Service

Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act or the SPIKE Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to determine at least annually whether certain covered drugs under Medicare were subject to a price increase that exceeded specified thresholds. Drug manufacturers must submit justifications for such price increases to the CMS, subject to civil penalties. The bill's requirements do not apply to low-cost drugs, as identified by the CMS.

 Related & companion bills 2
  • HR 4418 Reintroduced Bill SPIKE Act
  • HR 2113 Prescription Drug STAR Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 10
All 10 Democratic 5 Republican 1
R
Steil, Bryan
Wisconsin · Nov 18, 2019
 D
Norton, Eleanor Holmes
District of Columbia · May 20, 2019
 D
Slotkin, Elissa
Michigan · May 20, 2019
Spanberger, Abigail
· May 2, 2019
 D
Case, Ed
Hawaii · Apr 30, 2019
 D
Houlahan, Chrissy
Pennsylvania · Apr 30, 2019
 D
Raskin, Jamie
Maryland · Apr 30, 2019
Cox, TJ
· Apr 8, 2019
Wild, Susan
· Apr 8, 2019
Reed, Tom
· Apr 3, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2069: SPIKE Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-2069/
MLA
"H.R. 2069: SPIKE Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-2069/.
Bluebook (legal)
H.R. 2069, 116th Cong. (2026), https://openamerica.io/bill/116-HR-2069/.
Markdown link
[H.R. 2069: SPIKE Act](https://openamerica.io/bill/116-HR-2069/)
Report a problem